Juxtafoveal choroidal neovascularization secondary to persistent placoid maculopathy treated with intravitreal bevacizumab.
OBJECTIVE
To describe a case of persistent placoid maculopathy (PPM) associated with juxtafoveal choroidal neovascularization (CNV) treated with intravitreal bevacizumab injection (IVBI).


METHODS
Interventional case report.


METHODS
A 60-year-old patient referred for sudden vision loss was diagnosed with PPM complicated by a disciform scar in the right eye and juxtafoveal CNV in the left eye, undergoing 2 IVBIs.


RESULTS
Best-corrected visual acuity passed from 20/32 to 20/20 after 2 IVBIs, with complete resolution of intraretinal and subretinal fluid and disappearance of fluorescein leakage.


CONCLUSIONS
IVBI is a promising treatment option for juxtafoveal CNV secondary to PPM.
Parodi
Maurizio Battaglia
MB
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy. maubp@yahoo.it
Iacono
Pierluigi
P
Bandello
Francesco
F
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000792:Angiography; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D004396:Coloring Agents; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D007208:Indocyanine Green; D056965:Injections, Intraocular; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000150:complications* / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology; D055213:Retinal Pigment Epithelium / Q000473:pathology*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D000068258:Bevacizumab; D007208:Indocyanine Green